Éric Lévesque
Chercheur universitaire clinicien
Axe Endocrinologie et néphrologie
Métastases et progression du cancer
Tumeurs cancéreuses solides
Urologie
Oncologie clinique
Pharmacogénomique
Publications
View all-
article Yu EY, Gratzke C, Burotto M, Zhang AY, Lévesque E, Ortega F, Peer A, Vile D, Chen ZH, Song Y, Schloss C, Todoric J, Garratt C, Poehlein C, Antonarakis ES, Fizazi K
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs
Future Oncol 22 (7), 2026.
-
article Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, Fradet Y, Lacombe L, Lévesque É and Marcoux N, Toren P, April G, Arsenault F, Beaulieu A, Singbo N, Veilleux C, Tremblay-Boily M, Tremblay V, Buteau FA, Beauregard JM
Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases t…
Can Urol Assoc J 20 (6), 2026.
-
article Feng T, Xie N, Gao L, Jia Q, Kung SH, Morova T, Li Y, Wang L, Fazli L, Lacombe L, Guillemette C, Lévesque E, Lack NA, Qi J, Han B, Dong X
Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression
J Clin Invest 136 (2), 2026.
Projects
- Découverte de biomarqueurs pronostiques et prédictifs en cancer de la prostate., from 2024-05-22 to 2027-05-22
- Non-invasive biomarkers and patient-reported outcomes for precision oncology in Prostate Cancer, from 2026-06-01 to 2029-05-31
- UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, from 2023-09-01 to 2025-08-31